Last updated: February 16, 2026
Overview
NDC 72603-0171 is a biosimilar drug, identified by its National Drug Code (NDC) number. Its primary indication is for the treatment of autoimmune conditions, specifically as a biosimilar to branded medicines such as Remicade (infliximab). It entered the biosimilar market in 2022, targeting the increasing demand for cost-effective biologic therapies.
Market Size and Growth Drivers
- Biologic Market: The global biologic drugs market was valued at approximately $375 billion in 2022, with biosimilars accounting for roughly $20 billion (5.3%). The market is projected to grow at a compound annual growth rate (CAGR) of 10-12% through 2030.
- Biosimilar Adoption: Adoption rates are rising as patent exclusivities for innovator biologics expire, particularly in North America and Europe. Estimated biosimilar penetration in autoimmune indications reached 30% in the U.S. in 2022, with expectations to surpass 50% by 2025.
- Pricing Pressure: Prices for biosimilars are typically 20-35% lower than their reference products initially, but they tend to decrease over time as market competition intensifies.
- Competitive Landscape: The biosimilar infliximab market has multiple entrants, including Pfizer’s Inflectra, Amgen’sAvsola, and Samsung Bioepis’s Renflexis.
Current Market Position of NDC 72603-0171
- Manufacture and Distribution: The product is produced by a major biosimilar manufacturer with FDA approval obtained in late 2022.
- Pricing Strategy: Launched at approximately 25% below the reference biologic, aligning with typical biosimilar pricing strategies.
- Market Share: As a new product, it holds an estimated 3-5% of the biosimilar infliximab market as of Q4 2022. Adoption depends on provider awareness, formulary inclusion, and payer coverage.
Price Projections
| Year |
Estimated Average Wholesale Price (AWP) |
Projected Market Share |
Estimated Revenue (millions USD) |
| 2023 |
$800 per vial |
5% |
$25 million |
| 2024 |
$780 per vial |
10% |
$70 million |
| 2025 |
$760 per vial |
20% |
$150 million |
| 2026 |
$740 per vial |
30% |
$250 million |
| 2027 |
$720 per vial |
40% |
$350 million |
Assumptions: Price declines reflect increased market penetration; the average vial price drops 2-3% annually due to competitive pressures. Revenues are based on estimated average weekly utilization across major healthcare settings—outpatient infusion centers and hospitals.
Pricing Trends
- Initial Launch: Biosimilar priced 25% below reference (reference infliximab priced ~$1,060 per vial). Price points tend to stabilize initially before declining.
- Mid-term Decline: As competition intensifies, prices decrease by approximately 3% annually, with further discounts within negotiated payer contracts.
- Long-term Outlook: By 2030, biosimilar infliximab prices may reach 60-70% of the reference price, depending on market dynamics.
Regulatory and Policy Impacts
- Patent Expirations: Patent cliff for infliximab in major markets from 2018-2022 opened entry points for biosimilars.
- Payer Policies: Formularies increasingly favor biosimilars, influencing pricing and market share.
- International Price Referencing: U.S. prices are influenced by prices in Europe and other jurisdictions, often leading to further discounts over time.
Risks and Opportunities
- Risks: Market share stagnation due to biosimilar hesitancy among providers, payer restrictions, and potential regulatory delays.
- Opportunities: Expanding into new indications, increasing formulary coverage, and participating in value-based healthcare initiatives could improve revenue streams.
Key Takeaways
- NDC 72603-0171 is positioned in a rapidly growing biosimilar market, with pricing estimates aligning with typical biosimilar discount trends relative to branded infliximab.
- Revenue growth hinges on market acceptance, payer negotiations, and competitive dynamics.
- Price reductions over time are expected, with projections showing steady declines as market penetration increases.
FAQs
- What factors influence biosimilar pricing? Biosimilar prices depend on manufacturing costs, competition intensity, payer negotiations, and regional policies.
- How does biosimilar market share typically evolve? Market share starts low post-launch but increases steadily over 2-3 years as prescriber confidence and formulary coverage improve.
- What are major challenges for biosimilar market entry? Challenges include limited provider familiarity, patent litigations, and payer restrictions.
- Is the NDC specific to a formulation or strength? Yes, the NDC specifies the exact formulation, strength, and packaging, influencing market segmentation.
- What is the typical lifecycle for biosimilar pricing? Prices are stable initially but decline progressively as increased competition and market saturation occur.
References
[1] IQVIA Biopharma Trends, 2022
[2] U.S. FDA Biosimilars Approval Data, 2022
[3] Evaluate Pharma, 2022
[4] CMS and Payer Policy Reports, 2022
[5] European Medicines Agency (EMA), Biosimilar Market Data, 2022
